phase 3 retatrutide Eli Lilly just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide phase 3 trial dosing

We carry it because the science supports it, and because our patients see measurable results when it's used consistently

It enhances the healing of muscle and tendon injuries by up-regulating VEGF expression, which is vital for angiogenesis and tissue repair

However, the mechanistic link between DPP4, p53, cellular senescence, and liver fibrosis could not be deduced from this study and warrants further investigation

Liraglutide, injectable semaglutide, and dulaglutide have shown statistically significant reductions in major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors

Melanotan-2 remains a research compound, not a therapeutic product

That conceptual shift may be as valuable as the compound itself